1	Reporting of Retrospective Registration in Clinical Trial Publications: a Cross-Sectional Study of
2	German Trials
3	
4	Martin Haslberger* (MH), <u>https://orcid.org/0000-0002-8067-2856</u> , <u>martin.haslberger@bih-</u>
5	<u>charite.de</u>
6	Stefanie Gestrich (SG), <u>stefanie.gestrich@charite.de</u>
7	Daniel Strech (DS), <u>https://orcid.org/0000-0002-9153-079X</u> , <u>daniel.strech@bih-charite.de</u>
8	
9	
10	Berlin Institute of Health at Charité – Universitätsmedizin Berlin, QUEST Center for Responsible
11	Research, Charitéplatz 1, 10117 Berlin, Germany
12	
13	* Corresponding author
14	
15	Keywords: Clinical Trials, Trial Registration, Reporting, Retrospective Registration
16	
17	

18 Abstract

Objective: Prospective registration has been widely implemented and accepted as a best practice in clinical research, but retrospective registration is still commonly found. We assessed to what extent retrospective registration is reported transparently in journal publications, and investigated factors associated with transparent reporting.

23 Design: We used a dataset of trials registered in ClinicalTrials.gov or Deutsches Register Klinischer 24 Studien, with a German University Medical Center as the lead center, completed 2009–2017, and 25 with a corresponding peer-reviewed results publication. We extracted all registration statements 26 from results publications of retrospectively registered trials and assessed whether they mention or 27 justify the retrospective registration. We analyzed associations of retrospective registration and 28 reporting thereof with registration number reporting, International Committee of Medical Journal 29 Editors (ICMJE) membership/-following and industry sponsorship using chi-squared or Fisher exact 30 test.

31 Results: In the dataset of 1927 trials with a corresponding results publication, 956 (53.7%) were 32 retrospectively registered. Of those, 2.2% (21) explicitly report the retrospective registration in the 33 abstract and 3.5% (33) in the full text. In 2.1% (20) of publications, authors provide an explanation 34 for the retrospective registration in the full text. Registration numbers were significantly 35 underreported in abstracts of retrospectively registered trials compared to prospectively registered 36 trials. Publications in ICMJE member journals did not have statistically significantly higher rates of 37 both prospective registration and disclosure of retrospective registration, and publications in 38 journals claiming to follow ICMJE recommendations showed statistically significantly lower rates 39 compared to non-ICMJE-following journals. Industry sponsorship of trials was significantly associated 40 with higher rates of prospective registration, but not with transparent registration reporting. 41 Conclusions: Contrary to ICMJE guidance, retrospective registration is disclosed and explained only 42 in a small number of retrospectively registered studies. Disclosure of the retrospective nature of the 43 registration would require a brief statement in the manuscript and could be easily implemented by 44 journals.

45	
46	
47	
48	
49	Strengths and limitations of this study
50 51 52	 We use a large, high-quality dataset of all trials conducted at German university medical centers and registered in two registries, with results publications determined by an extensive manual screening process.
53 54	 We consider a period of nine years (2009 – 2017) and describe the development of reporting practices over time
55 56 57	 This study only includes trials led by German university medical centers, reflecting German regulatory standards.

58 Introduction

59 Prospective registration of clinical trials (i.e., registration before enrollment of the first participant) is 60 an important practice to reduce biases in their conduct and reporting (1). A number of ethical and 61 legal documents call for prospective registration: The Declaration of Helsinki (2) and the World 62 Health Organization registry standards (3) state that prospective registration and results reporting of 63 clinical trials are an ethical responsibility. European law, for example, explicitly mandates 64 prospective registration of pharmaceutical trials (4). In addition, many journals, via the International 65 Committee of Medical Journal Editors (ICMJE), encourage or require prospective registration with an 66 appropriate registry before the first participant is enrolled for all trials they publish, as well as the 67 reporting of trial registration numbers (TRNs) in publications for better findability (5,6). Similarly, 68 reporting guidelines such as Consolidated Standards of Reporting Trials (CONSORT) (7) and Good Publication Practice 3 (GPP3) (8) recommend the reporting of trial registration numbers. 69 70 Prospective registration has been widely implemented and advocated for many reasons: to detect 71 and mitigate publication bias (i.e., the non-reporting of studies, or aspects of studies, that did not 72 yield a positive result) and selective reporting (i.e., the selective reporting of only statistically 73 significant primary outcomes). Prospective registration allows for public scrutiny of trials, 74 identification of research gaps and to support the coordination of efforts by preventing unnecessary 75 duplication (9). When trials are registered retrospectively, i.e., their registry entry is created after 76 study start, this undermines the many of the reasons for registration. While prospective registration has increased over the past decade, retrospective registration is still widespread (10-14). Some 77 78 registries, such as Deutsches Register Klinischer Studien (DRKS) or the WHO's International Clinical 79 Trials Registry Platform, explicitly mark retrospectively registered entries as such, whereas others, 80 such as ClinicalTrials.gov, do not. While some journal editors allow retrospectively registered trials to 81 be published, others do not. Journals following ICMJE guidance should in principle mandate 82 prospective registration, but this principle is not always enforced (12,15,16). According to ICMJE 83 guidance, journals should publish retrospectively registered studies only in exceptional cases, noting 84 that "authors should indicate in the publication when registration was completed and why it was 85 delayed. Editors should publish a statement indicating why an exception was allowed." (5) This was 86 investigated by previous studies which found that such reporting rarely happens (17,18). 87 Our study aims to investigate the conduct of retrospective registration and its transparent reporting 88 in a larger sample. In a previous study in a cohort of 1509 trials conducted at German University 89 Medical Centers (UMC), registered in DRKS or ClinicalTrials.gov, and reported as complete between 90 2009-2013, 75% were registered retrospectively (19). This rate dropped to 46% for the 1658 trials 91 completed between 2014-2017 (20). Using the data from these two studies on trials registered in 92 two large registries, led by German UMCs, completed between 2009 and 2017, and with at least one 93 available peer-reviewed results publication (19,20), we investigate whether and how authors report 94 retrospective registration in the results publication. We also explore how retrospective registration 95 is associated with other practices such as TRN reporting. 96

97 Methods

98Data sources and sample. We based our sample on two related projects that were conducted at our99research group (19,20). The projects have drawn a full sample (n = 3113) of registry entries for100interventional studies reported as complete between 2009 and 2017, led by a German UMC and101registered in one of two registries: DRKS, which is the WHO primary trial registry for Germany, and102ClinicalTrials.gov, which is also routinely used in Germany to register clinical research and accepted

103 by the ICMJE. Our dataset also includes the earliest results publications found for 68.4% (2129/3113) 104 of the trials, which were manually identified in different stages until September 1st, 2020. We 105 retrieved the combined data from the two projects from a GitHub repository 106 (https://github.com/maia-sh/intovalue-data, accessed 22.02.2022). The final dataset is publicly 107 available (21). 108 *Eligibility criteria*. We included any trial that [1] was registered as an interventional study in either 109 the ClinicalTrials.gov or the DRKS database, [2] was completed between 2009 and 2017, [3] reports a 110 German UMC listed as the responsible party or lead sponsor, or with a principal investigator from a 111 German UMC, [4] has published results in a peer-reviewed journal. Detailed descriptions of how 112 these variables were derived are provided in the original publications of the dataset (19,20). 113 Retrospective registration was determined based on the registration and study start dates in the 114 registry entries: dates were set to the first of the respective month and studies with a registration 115 date more than one month after start date counted as retrospectively registered. For trials that were 116 registered in both registries, we kept the entry that was created earlier. 117 Data extraction. For all retrospectively registered trials, we manually searched the abstract and the 118 full text of the publications, including editorial statements, whether they reported 119 the fact that the study was registered (binary), 120 • a trial registration number (binary), 121 the exact wording used to report the registration, including any provided registration • 122 numbers (free text), 123 the date of the retrospective registration (binary), and • 124 the fact that the study was retrospectively registered (binary). • 125 We also assessed whether (binary) and how authors justified or explained the retrospective • 126 registration (free text). 127 One rater (MH) used the keywords "regist", "nct", "drks", "eudra", "retro", "delay", and "after" to 128 search for registration numbers and wording pointing to retrospective registration in all publications. 129 We considered a retrospective registration statement transparent if the authors explicitly mentioned that the registration was retrospective, e.g., "this study was retrospectively registered in [registry], 130 131 [TRN]". Reporting of the registration date alone was not considered as transparent reporting of retrospective registration, except if the date of registration was mentioned in combination with the 132 133 study start date in the same paragraph. 134 *ICMJE journals.* We created additional variables for whether journals are ICMJE members or follow 135 the ICMJE recommendations (22). 136 Cross-registrations. We classified all retrospectively registered studies in our sample that also report 137 a registration in EudraCT in the publication as prospective, as registrations on the platform are 138 required prior to the approval of regulatory agencies or research ethics committees (4). 139 Reliability assessment of ratings. To assess the reliability of the data extraction, another rater (SG) 140 performed three validation steps: first, a sample of 100 publications was screened using the same 141 extraction form, during the main screening to refine category definitions. Second, another sample of 142 100 publications for which no registration number reporting was noted by MH to check for false 143 negative ratings. Third, all cases with either date, or reporting of retrospective registration or 144 justification were screened, to check for false positives. 145 Analyses 146 Associations between prospective registration and other variables. To test the strength of the 147 associations between prospective registration and three variables, we used Pearson's chi-squared

148	independence test. These variables were (1) publication in a ICMJE member journal or a journal
149	following ICMJE recommendations, (2) reporting of a registration number, and (3) industry funding.
150	Associations between reporting of retrospective registration and other variables. To test the strength
151	of the associations between the reporting of retrospective registration and two binary variables, we
152	used_Fisher's exact test, as case numbers were low. These variables are (1) publication in a ICMJE
153	member journal or a journal following ICMJE recommendations, and (2) industry funding.
154	Software
155	We used Microsoft Excel for data collection and R (version 4.0.3) for data analysis and visualization.
156	
157	Reporting
158	We checked our manuscript against the STROBE checklist (supplementary Table 1) (23).
159	
160	Patient and Public Involvement
161	No patient involved.
162	
163	Results
164	Sample of retrospectively registered trials. After applying the above-mentioned exclusion criteria,
165	1932 registered studies with an associated results publication remained. Of these, 1038 (54%) were
166	retrospectively registered according to the information provided in ClinicalTrials.gov and DRKS. We
167	screened these 1038 studies for our analysis. Five of the publications were excluded as they were
168	mislabeled as results publications in the dataset. Another 77 (8%) of the publications provided a
169	EudraCT number, in which case we reclassified the study as prospectively registered, leaving 956
170	studies. For statistical comparisons, we used the studies classified as prospectively registered
171	(n=971) in the dataset as a control group. A flowchart of this study selection is provided in Figure 1.
172	Basic characteristics of included trials are available in supplementary Table 2.
173	
174	Retrospective registration. Figure 2 shows the extent of retrospective registration over time, which
175	has been falling steadily from 100% in 2004 to 25% in 2017.
176	We describe associations between prospective registration and previously defined binary variables
177	in Table 1: We found no statistically significant association between publication in ICMJE member
178	journals and prospective registration (p=0.10). Similarly, we found no statistically significant
179	association with prospective registration when also including publication in journals reporting to
180	follow ICMJE recommendations (p=0.47). It is important to note here that the information on ICMJE-
181	following is based on journals' requests to be included on the ICMJE website as a journal following
182	the ICMJE's recommendations (22), therefore our results suggest that journals requesting to be
183	listed on the site often do not enforce the recommendations strongly. However, there are other
184	journals, such as many PLOS journals, that are not featured on the ICMJE site, but implement the
185	recommendations. Retrospectively registered trials, compared to prospectively registered trials
186	significantly underreported registration numbers in the abstract (p = 0.0007). Industry sponsorship
187	of trials was associated with prospective registration (p = 0.002). In 31% (294/956) of trials,
188	registration occurred between study completion and publication (median 370 days before
189	publication). Another 3% (25/956) of trials were registered after publication (median 249 days after
190	publication).
191	

192 Table 1: Associations between prospective registration and other variables

Variable (Yes/No)		n (%) prospectively registered	P-value (Chi-sq.)
ICMJE member journal	Y	28 (63.6%)	p = 0.10
	Ν	943 (50.1%)	
ICMJE member/following journal	Y	329 (49.2%)	p = 0.47
	Ν	642 (51.0%)	
TRN reporting in abstract	Y	404 (55.4%)	p = 0.0007
	Ν	567 (47.3%)	
Industry sponsorship	Y	163 (59.3%)	p = 0.002
	Ν	808 (48.9%)	

193

194 Reporting of registration. Table 2 summarizes the prevalence of reporting of trial registration and

195 the reporting of retrospective registration. In 82% (783/956) of the remaining results publications of

196 retrospectively registered trials, the registration was explicitly reported in either the abstract or the

197 full text. In all except four of these publications, the registration was mentioned by providing the

198 registration number. In the other cases, the registration was mentioned but without reporting a

199 registration number.

200

201 Table 2: Number of retrospectively registered trials and prevalence of key retrospective registration 202 reporting practices.

- * "other" includes footnotes, sidebars, etc.
- 203

% (of total) n 956 100.0% **Total: Retrospectively registered trials Registration reported** 783 81.9% **Registration number reported** 779 81.5% 325 34.0% in abstract in full-text 535 56.0% in other* 134 14.0% **Registration date reported** 67 7.0% in abstract 45 4.7% in full-text 32 3.3% **Retrospective registration addressed** 47 4.9% 2.2% in abstract 21 in full-text 33 3.5% Retrospective registration justified/explained 20 2.1% 0 in abstract 0.0% in full-text 20 2.1%

204

205 Reporting of retrospective registration. The rate of trials for which retrospective registration is

206 reported transparently increased over the last years up to 15% in 2020 (Figure 3). Overall, among all

207 956 retrospectively registered clinical studies, five percent (47) mention explicitly that this

208 registration was retrospective in the abstract or full text (see Table 2). Among those cases, 20 give

- some explanation or justification for why registration was retrospective. In seven percent (67) of
- 210 cases, the authors reported the registration date alongside the registration statement, but in 35 of
- those, the date was provided without giving the necessary context that the registration was
- 212 retrospective.
- 213 Publications in ICMJE member journals did not have a statistically significantly higher rate of
- reporting of retrospective registration (13% vs. 5%, p = 0.18), whereas publications in ICMJE member
- or -following journals had a significantly lower rate (2% vs. 7%, p = 0.004). We found no association
- 216 with transparent reporting of retrospective registration for industry sponsored trials (2% vs. 5%, p =
- 217 0.16) (Table 3).
- 218

219 Table 3: Associations between transparent reporting of retrospective registration and other variables

Variable (Yes/No)		n (%) reporting RR	P-value (Fisher test)
ICMJE member journal	Y	2 (12.5%)	p = 0.18
	Ν	45 (4.8%)	
ICMJE member/following journal	Y	7 (2.1%)	p = 0.004
	Ν	40 (6.5%)	
Industry sponsorship	Y	2 (1.8%)	p = 0.16
	Ν	45 (5.3%)	

220

221 *Justifications of retrospective registration.* In 20 cases in which the retrospective nature of the

222 registration was reported, the authors provided further information explaining or justifying the

retrospective registration. Notably, 14 of the 20 studies (70%) that justified the retrospective

- registration were published in a single journal, PLOS ONE. Table 4 shows the main themes present in
- 225 authors' explanations, with text examples.
- 226

227 Table 4. Main themes identified from authors' explanations of retrospective reporting and example

228 statements.

statements.	
Theme	Example(s)
Unawareness of	"At the time when the trial was started, the initiators of this study were unfortunately unaware
registration policy	of the policy of the International Committee of Medical Journal Editors (ICMJE), which requires
	prospective registration of all interventional clinical trials. As soon as we became aware of this
	policy, we registered the trial." (doi: 10.1371/journal.pone.0146678)
	"The reason for retrospectively registering the study was that the study authors were not aware
	of the recommendation to register diagnostic accuracy studies before this date." (doi:
	10.1371/journal.pone.0199345)
Delays by the	"Registration of the study was applied for in April 2015. All queries from the DRKS were
registry	answered until the 31st August 2015 except the planned inclusion date of the first patient (first-
	patient-in), which was correct in the DRKS registry on 1st December 2015. Confirmation of
	registration occurred on 4th December 2015. The first patient was recruited and randomized
	into the study on 20th October 2015. Until 4th December 2015 eight patients were randomized
	into the trial." (doi: 10.1371/journal.pone.0229898)
Not obligatory at	"At the time of submission of the study protocol, the Ethics Committee did not require
the time	registration for feasibility or proof of concept studies. The study was registered in
	ClinicalTrials.gov (NCT02196545) in July 2014 in preparation of a manuscript for publication of
	the data. The authors confirm that all ongoing and related trials for this intervention are
	registered." (doi: 10.1371/journal.pone.0121478)

Not obligatory for the intervention	"It was not registered at a clinical trial register, because at the time of setup in 2003, such a registration was not obligatory." (doi: 10.2174/1874325001307010133) "According to national laws it is stipulated to inform the respective ethics committee, but it was not necessary to register the study in an official registry or to obtain an ethics committee vote, because it was an expanded access study (Heilversuch). Despite this, we prospectively obtained
e ,	"According to national laws it is stipulated to inform the respective ethics committee, but it was not necessary to register the study in an official registry or to obtain an ethics committee vote,
e ,	not necessary to register the study in an official registry or to obtain an ethics committee vote,
the intervention	
	because it was an expanded access study (Heilversuch). Despite this, we prospectively obtained
	a vote of the ethics committee. Study design and patient information form were approved by
	the local ethics committee (ethics committee of the regional medical association; approval no.
	EK-BR-50/10-1, date of approval December 10th, 2010). In addition, the study was registered at
	www.clinicaltrials.gov (ID no. NCT02168790)." (doi: 10.1371/journal.pone.0125035)
Miscommunnication	"The time of first registration was June 17, 2013, and final approved trial registration was July 1,
between	2013. First patient inclusion was in July 2012 at the Heart Center Leipzig University Hospital,
investigators	Leipzig, Germany. Thus, there was a delay between first patient inclusion and trial registration
U	that was the result of a misunderstanding between the principal investigator of the trial, Dr
	Thiele, and the first author, Dr Fuernau, who was responsible for clinical project coordination at
	the investigator's site at the Heart Center Leipzig University of Leipzig. According to initial
	communication, registration had to be performed by Dr Fuernau. When the study principal
	investigator recognized that it had not been performed, we immediately registered the trial at http://www.ClinicalTrials.gov. At this time, only 7 patients at the Heart Center Leipzig University
	Hospital had been included in the trial." (doi: 10.1161/CIRCULATIONAHA.117.032722)
	"[] there was a delay of trial registration before first patient inclusion which was induced by a
	misunderstanding between the project coordination for the EU grant (at this time gabo:mi, later
	on ARTTIC) and the clinical project coordination at the investigator's site at the Heart Center
	Leipzig - University of Leipzig. According to initial communication registration should be
	performed by gabo:mi. When the study coordinator recognized that it has not been performed
	we immediately registered it at <u>clinicaltrials.gov</u> . At this time only 13 patients at the Heart
	Center Leipzig University Hospital (and no other study site) have been included into the trial."
Dublication	(doi: 10.1056/NEJMoa1710261)
Publication	"Registration was done after the study has been conducted and the results suggested a
	publication and further continuation of this research." (doi: 10.1186/s12903-016-0264-2)
Confidentiality	"The principal investigator (N.H.) delayed the registration of the study until data acquisition was
	completed for confidentiality reasons concerning the study methods, especially the magnetic
	resonance with the related morphometric measurements." (doi: 10.1371/journal.pone.0136375)
Logistic/	"Because of administrative problems, release of registration occurred about six months after
Administrative	study start. The authors confirm that all ongoing and related trials for this intervention are
issues	registered." (doi: 10.1371/journal.pone.0220436)
	"Due to organisational changes in the research project shortly before the start of the
	recruitment we put great efforts into avoiding a delayed start of the data collection in the
	"Registration of the trial was delayed after the enrollment of the first patient due to an
	administrative error. The authors confirm that all ongoing and related trials for this intervention
	are registered." (doi: 10.1371/journal.pone.0140584)
	administrative error. The authors confirm that all ongoing and related trials for this intervention

229

230

231 Discussion

- 232 In this study we show that in a sample of 956 results publications from retrospectively registered
- clinical studies led by German UMCs and completed between 2009 and 2017, only a small number of
- 234 publications (5%) make the retrospective nature of the registration transparent, and even fewer
- 235 (2%) explain the reasons for retrospective registration. To our knowledge, two studies have
- previously quantified the reporting of retrospective registration: Al-Durra et al. (17) found in a
- sample of 286 publications in ICMJE member journals and published in 2018 that only three percent
- 238 (8/286) of papers of retrospectively registered trials in their sample include justifications or
- explanations for delayed registration. Similarly, Loder et al. (18), in their analysis of 70 papers

- submitted to the British Medical Journal from 2012-2015 and rejected for registration issues, found
- that three percent (2/70) disclosed the registration problem when published in another journal. Our
- 242 study finds a slightly lower percentage of two percent for explanations of the reasons for
- 243 retrospective registration, but a higher percentage of five percent for disclosure in a larger sample
- representing a broader selection of journals and extended time frame.
- 245 We found that publications were not significantly more often prospectively registered when they
- 246 were published in ICMJE member journals or in journals following ICMJE recommendations, but
- showed a significantly higher rate of TRN reporting. A similar result was found by Al-Durra et al. (17).
- 248 Further, we found that transparent reporting of retrospective registration does not happen
- significantly more often in publications in ICMJE member journals, and is even happening at a
- significantly lower rate in journals listed as following ICMJE recommendations.
- There were different reasons for retrospective registration brought forth by authors, many of which have been described previously (15,17,18,24). In some cases, authors raise points that lie outside
- 253 their direct responsibility, such as delays caused by the registry or research not being legally
- required to be preregistered. Several other reasons provided were within authors' control, such as
- logistic and administrative issues, miscommunication between researchers or unawareness of
- registration policies. In some cases, authors report registering a study to meet journal editorial
- 257 policies even though registration would not be required for the kind of research otherwise. This is
- also possibly reflected in the fact that almost a third (31%) of retrospectively registered studies in
- our sample have been registered between study completion and publication. In one publication, the
- authors transparently describe that the registration occurred only when "results suggested a
- 261 publication and further continuation of this research", which has been previously described as
- 262 "selective registration bias" (17) and is explicitly called out in ICMJE guidance as it "meets none of
- the purposes of preregistration" (5). Another identified theme revolves around the confidentiality of
- 264 methods however, in this case many other details about the trial could have been preregistered.
- 265 Limitations
- 266 For feasibility and data quality reasons, our study was based on an existing validated dataset, 267 containing only trials led by German UMCs, which might limit its generalizability to other regions. 268 However, the sample also contained multi-center trials with other countries involved and is larger 269 and from a wider variety of journals compared to previous studies (17,18). Our analysis of 270 retrospective registration is based on trial start dates and registration dates as provided by the two 271 registries used for sampling: Clinicaltrials.gov and DRKS. It is possible that authors did not update 272 their registry entries when delays to the start date occurred. For example, we did not specifically 273 follow up cases in which authors wrote that a trial was registered prospectively, but the registry 274 dates did not reflect that statement. In order not to reduce the sample size, we also did not correct 275 for varying follow-up in the identification of result publications, e.g., by limiting our analysis to 276 publications published within 2 years of trial completion. However, this means that the newer trials 277 in the sample (i.e., years 2016, 2017) might not reflect the complete research output of those years 278 as some trials may not have been published by the end of follow-up in 2020 and were therefore 279 excluded from the analysis. The numbers presented in Figures 2 and 3 may overestimate the 280 improvements in prospective registration as trials reporting results on time might likely generally 281 show a higher quality of registration conduct and might therefore be registered prospectively at a 282 higher rate.

In our analyses involving the classification into ICMJE-following and non-following journals, we relied
 on the data provided on the ICMJE website (icmje.org), which are self-reported by journals, i.e., a
 journal must write to the ICMJE that they want to be included in the list. Thus, there are some
 journals missing in the ICMJE data and therefore in our dataset. For ICMJE member journals (n=12)

- 287 on the other hand, there is a complete listing available.
- 288
- 289 Conclusion

290 The Declaration of Helsinki and other guidelines for responsible clinical research unanimously 291 recommend prospective registration of all clinical research (2). For clinical trials regulated by drug 292 and device regulatory authorities, this was codified into law (4). A major aim of prospective 293 registration is to minimize the risk of undisclosed changes to the protocol after the study started and 294 first results are analyzed. When registration happens retrospectively, this major goal is not 295 addressed. The reporting of study registration is generally considered a best practice to make a 296 study more trustworthy. In the case of retrospective registration, in contrast, reporting registration 297 without transparency on the retrospective nature should rather raise concerns as readers might 298 wrongly interpret the mentioning of registration as a quality criterion. This could be considered 299 "performative reproducibility", i.e., the "pretence of reproducibility without the reality" (25). Journal 300 editors and reviewers could enforce explicit reporting and explanation of retrospective registration, 301 but we found that this rarely happens. To fulfill the ICMJE requirements on reporting retrospective registration, a simple note in the registration statement of the paper would suffice, such as: "This 302 303 study was retrospectively registered as [TRN] at [Registry], [X] days after the trial started because 304 [Reason]".

305 306

307 Ethics approval

308 Not applicable

309

310 Contributorship statement

- 311 Martin Haslberger Conceptualization, methodology, investigation, analysis, writing original draft,
- 312 project management
- 313 Stefanie Gestrich Methodology, investigation
- Daniel Strech Conceptualization, methodology, supervision, writing review and editing, funding
 acquisition
- 210 200
- 316 317

318 Competing interests

319 The authors declare no competing interests.

320

321 Funding

322 This work was partly funded under a grant from the Federal Ministry of Education and Research of

- 323 Germany (Bundesministerium fuer Bildung und Forschung BMBF) [01PW18012]. The funder was
- not involved in the study design, data collection, analysis, or interpretation, writing of the
- 325 manuscript, or the decision to submit for publication.
- 326
- 327 Data sharing statement

- 328 All code and the data for this study are available at https://github.com/mhaslberger/retrospective-
- registration. Data are also available in an OSF repository (https://osf.io/8g5cf/).
- 330

331 Acknowledgments

- 332 We thank Maia Salholz-Hillel for conceptual feedback and technical support. We thank Martin R.
- 333 Holst and Dr. Delwen Franzen for feedback on the manuscript.

335 References

Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol.
 1986 Oct;4(10):1529-41.

WMA. World Medical Association: Declaration of Helsinki - Ethical Principles for Medical
 Research involving Human Subjects [Internet]. 2018. Available from: https://www.wma.net/policies post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

World Health Organization. International standards for clinical trial registries: the
 registration of all interventional trials is a scientific, ethical and moral responsibility [Internet].
 version 3.0. Geneva: World Health Organization; 2018 [cited 2022 Feb 1]. 48 p. Available from:

344 https://apps.who.int/iris/handle/10665/274994

4. European Medicines Agency. Regulation (EU) No 536/2014 of the European Parliament and
of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing
Directive 2001/20/EC [Internet]. Jan 31, 2022. Available from:

348 http://data.europa.eu/eli/reg/2014/536/2022-01-31

3495.ICMJE. International Committee of Medical Journal Editors Recommendations for the350Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals [Internet]. [cited3512021 Oct 18]. Available from: http://www.icmje.org/icmje-recommendations.pdf

De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration:
 a statement from the International Committee of Medical Journal Editors. Lancet Lond Engl. 2004
 Sep 11;364(9438):911–2.

Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010
 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ.
 2010 Mar 23;340(mar23 1):c869–c869.

Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication
 Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015
 Sep 15;163(6):461–4.

361 9. Zarin DA, Keselman A. Registering a Clinical Trial in Clinical Trials.gov. Chest. 2007
362 Mar;131(3):909-12.

36310.Trinquart L, Dunn AG, Bourgeois FT. Registration of published randomized trials: a systematic364review and meta-analysis. BMC Med. 2018 Oct 16;16(1):173.

Birajdar AR, Bose D, Nishandar TB, Shende AA, Thatte UM, Gogtay NJ. An audit of studies
registered retrospectively with the Clinical Trials Registry of India: A one year analysis. Perspect Clin
Res. 2019 Mar;10(1):26–30.

Scott A, Rucklidge JJ, Mulder RT. Is Mandatory Prospective Trial Registration Working to
Prevent Publication of Unregistered Trials and Selective Outcome Reporting? An Observational Study
of Five Psychiatry Journals That Mandate Prospective Clinical Trial Registration. Wicherts JM, editor.
PLOS ONE. 2015 Aug 19;10(8):e0133718.

Mann E, Nguyen N, Fleischer S, Meyer G. Compliance with trial registration in five core
journals of clinical geriatrics: a survey of original publications on randomised controlled trials from
2008 to 2012. Age Ageing. 2014 Nov;43(6):872–6.

375 14. Smaïl-Faugeron V, Fron-Chabouis H, Durieux P. Clinical trial registration in oral health
376 journals. J Dent Res. 2015 Mar;94(3 Suppl):8S-13S.

Harriman SL, Patel J. When are clinical trials registered? An analysis of prospective versus
 retrospective registration. Trials. 2016 Apr 15;17:187.

Boughton S. Retrospectively registered trials: the Editors' dilemma [Internet]. Research in
progress blog. 2016 [cited 2022 Jul 21]. Available from:

https://blogs.biomedcentral.com/bmcblog/2016/04/15/retrospectively-registered-trials-editors dilemma/

Al-Durra M, Nolan RP, Seto E, Cafazzo JA. Prospective registration and reporting of trial
 number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and
 Declaration of Helsinki recommendations. BMJ. 2020 Apr 14;m982.

18. Loder E, Loder S, Cook S. Characteristics and publication fate of unregistered and
 retrospectively registered clinical trials submitted to The BMJ over 4 years. BMJ Open. 2018 Feb
 16;8(2):e020037.

Wieschowski S, Riedel N, Wollmann K, Kahrass H, Müller-Ohlraun S, Schürmann C, et al.
Result dissemination from clinical trials conducted at German university medical centers was
delayed and incomplete. J Clin Epidemiol. 2019 Nov;115:37–45.

Riedel N, Wieschowski S, Bruckner T, Holst MR, Kahrass H, Nury E, et al. Results
dissemination from completed clinical trials conducted at German university medical centers
remained delayed and incomplete. The 2014 –2017 cohort. J Clin Epidemiol. 2022 Apr;144:1–7.

21. [dataset] Haslberger M, Gestrich S, Strech D. Reporting of Retrospective Registration in
Clinical Trial Publications [Internet]. 2023. Available from: https://osf.io/8g5cf/


397 22. ICMJE. Journals stating that they follow the ICMJE Recommendations [Internet]. [cited 2022
 398 Apr 7]. Available from: http://www.icmje.org/journals-following-the-icmje-recommendations/

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
guidelines for reporting observational studies. Lancet Lond Engl. 2007 Oct 20;370(9596):1453–7.


402 24. Hunter KE, Seidler AL, Askie LM. Prospective registration trends, reasons for retrospective
403 registration and mechanisms to increase prospective registration compliance: descriptive analysis
404 and survey. BMJ Open. 2018 Mar 1;8(3):e019983.

405 25. Buck S. Beware performative reproducibility. Nature. 2021 Jul 8;595(7866):151–151.

- 407 Figure 1: Flowchart of in-/exclusion of studies. From the 1038 trials that were retrospectively
- 408 registered in Clincialtrials.gov or DRKS, we excluded 5 publications that clearly did not report clinical
- 409 study results (e.g., secondary analyses of CT data) and another 77 that reported EudraCT entries in
- the publications, resulting in 956 retrospectively registered studies from a total dataset of 1927 (971
- 411 + 956) studies.



- 415 Figure 2: Percentage of retrospectively registered (RR) trials over time (per study start year). GAM
- 416 (generalized additive model) smoother laid over (blue) with 95% confidence interval. Bubble sizes
- 417 indicate the number of trials per year included in the dataset.





- 421 Figure 3: Percentage of retrospectively registered trials reporting retrospective registration
- 422 transparently in the publication over time (per study publication year). GAM (generalized additive
- 423 model) smoother laid over (blue) with 95% confidence interval. Bubble sizes indicate the number of
- 424 trials per year included in the dataset. Starting in 2013, some authors begin to report retrospective
- 425 registration. 15% of publications of retrospectively registered trials from 2020 transparently report
- 426 retrospective registration. Four trials were published before 2009 in all those cases the study
- 427 completion dates provided in the registry were after 2009. Study start dates were before 2005 and
- studies were registered in 2005 (3/4) or later (1/4).

